Therapeutics and Vaccines Against Pathogenic Escherichia coli

  • Marina S. PalermoEmail author
  • José Flores-Figueroa
  • Mercedes Paredes-Paredes


Diarrheagenic E. coli continues to be an important pathogen causing significant illness in animals and humans. Despite the fact that considerable investigations have been done following the initial discovery of enterotoxigenic Escherichia coli (ETEC) and enterohemorrhagic E. coli (EHEC), there are currently no available licensed and broadly protective, ETEC nor EHEC vaccines. The significant, yet unsuccessful efforts in obtaining a vaccine candidate have provided important information on strategies to consider in future formulations. There are now new promising vaccine candidates based on this pioneering work, even though they have not generated successful vaccines. This chapter is focused on outstanding findings and their impact in human public health.




  1. Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC (2006) Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2–5 year-old children. J Infect Dis 193:515–521PubMedCrossRefGoogle Scholar
  2. Ahn CK, Klein E, Tarr PI (2008) Isolation of patients acutely infected with Escherichia coli O157:H7: low-tech, highly effective prevention of hemolytic uremic syndrome. Clin Infect Dis 46:1197–1199PubMedCrossRefGoogle Scholar
  3. Akiyoshi DE, Sheoran AS, Rich CM, Richard L, Chapman-Bonofiglio S, Tzipori S (2010) Evaluation of Fab and F(ab′)2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2. Infect Immun 78:1376–1382PubMedPubMedCentralCrossRefGoogle Scholar
  4. Allen K, Rogan D, Finlay B, Potter A, Asper D (2011) Vaccination with type III secreted proteins leads to decreased shedding in calves after experimental infection with Escherichia coli O157. Can J Vet Res 75:98–105PubMedPubMedCentralGoogle Scholar
  5. Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Astuias E, Pauwells HL, Maxwell R, Paredes-Paredes M, Glenn GM, Dewasthaly S, Stablein DM, Jiang ZD, Dupont HL (2014) Efficacy and safety of a patch vaccine containing heat labile toxin from Escherichia coli against travelers’ diarrhoea: a phase 3, randomized, double-blind, placebo-controlled field trial in travelers from Europe to Mexico and Guatemala. Lancet Infect Dis 14:197–204PubMedCrossRefGoogle Scholar
  6. Bentancor LV, Bilen M, Brando RJ, Ramos MV, Ferreira LC, Ghiringhelli PD, Palermo MS (2009) A DNA vaccine encoding the enterohemorrhagic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin Vaccine Immunol 16:712–718PubMedPubMedCentralCrossRefGoogle Scholar
  7. Berry ED, Wells JE (2012) Soil solarization reduces Escherichia coli O157: H7 and total Escherichia coli on cattle feedlot pen surfaces. J Food Prot 75:7–13PubMedCrossRefGoogle Scholar
  8. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H (2012) Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 56:3277–3282PubMedPubMedCentralCrossRefGoogle Scholar
  9. Bitzan M, Poole R, Mehran M, Sicard E, Brockus C, Thuning-Roberson C, Rivière M (2009) Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 53:3081–3087PubMedPubMedCentralCrossRefGoogle Scholar
  10. Boisen N, Scheutz F, Rasko DA et al (2012) Genomic characterization of enteroaggregative Escherichia coli from children in Mali. J Infect Dis 205(3):431–444PubMedCrossRefGoogle Scholar
  11. Bourgeois AL, Wierzba TF, Walker RI (2016) Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine 34:2880–2886PubMedCrossRefGoogle Scholar
  12. Burlaka I, Liu XL, Rebetz J, Arvidsson I, Yang L, Brismar H, Karpman D, Aperia A (2013) Ouabain protects against Shiga toxin-triggered apoptosis by reversing the imbalance between Bax and Bcl-xL. J Am Soc Nephrol 24:1413–1423PubMedPubMedCentralCrossRefGoogle Scholar
  13. Cai K, Gao X, Li T, Hou X, Wang Q, Liu H, Xiao L, Tu W, Liu Y, Shi J, Wang H (2010) Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response. Can J Microbiol 56:389–398PubMedCrossRefGoogle Scholar
  14. Cai K, Gao X, Li T, Wang Q, Hou X, Tu W, Xiao L, Tian M, Liu Y, Wang H (2011) Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 29:946–952PubMedCrossRefGoogle Scholar
  15. Callaway TR, Carr MA, Edrington TS, Anderson RC, Nisbet DJ (2009) Diet, Escherichia coli O157:H7, and cattle: a review after 10 years. Curr Issues Mol Biol 11:67–79PubMedGoogle Scholar
  16. Carey CM, Kostrzynska M, Ojha S, Thompson S (2008) The effect of probiotics and organic acids on Shiga-toxin 2 gene expression in enterohemorrhagic Escherichia coli O157:H7. J Microbiol Methods 73:125–132PubMedCrossRefGoogle Scholar
  17. Chen YP, Lee TY, Hong WS, Hsieh HH, Chen MJ (2013) Effects of Lactobacillus kefiranofaciens M1 isolated from kefir grains on enterohemorrhagic Escherichia coli infection using mouse and intestinal cell models. J Dairy Sci 96:7467–7477PubMedCrossRefGoogle Scholar
  18. Cheng LW, Henderson TD, Patfield S, Stanker LH, He X (2013) Mouse in vivo neutralization of Escherichia coli Shiga toxin 2 with monoclonal antibodies. Toxins 5:1845–1858PubMedPubMedCentralCrossRefGoogle Scholar
  19. Choi KS, Kim SH, Kim ED, Lee SH, Han SJ, Yoon S, Chang KT, Seo KY (2014) Protection from hemolytic uremic syndrome by eye drop vaccination with modified enterohemorrhagic E. coli outer membrane vesicles. PLoS One 9:e100229PubMedPubMedCentralCrossRefGoogle Scholar
  20. Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR (1988) Cross-protection by B subunitwhole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158:372–7PubMedCrossRefGoogle Scholar
  21. Crane JK, Byrd IW, Boedeker EC (2011) Virulence inhibition by zinc in Shiga-toxigenic Escherichia coli. Infect Immun 79:1696–1705PubMedPubMedCentralCrossRefGoogle Scholar
  22. Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker RI, Harro CD (2012) The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 19:1921–1931PubMedPubMedCentralCrossRefGoogle Scholar
  23. Del Canto F, Valenzuela P, Cantero L, Bronstein J, Blanco JE, Blanco J, Prado V, Levine M, Nataro J, Sommerfelt H, Vidal R (2011) Distribution of classical and non classical virulence genes in enterotoxigenic Escherichia coli isolates from Chilean children and tRNA gene screening for putative insertion sites for genomic islands. J Clin Microbiol 49:3198–3203PubMedPubMedCentralCrossRefGoogle Scholar
  24. Dowling TC, Chavaillaz PA, Young DG, Melton-Celsa A, O’Brien A, Thuning-Roberson C, Edelman R, Tacket CO (2005) Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 49:1808–1812PubMedPubMedCentralCrossRefGoogle Scholar
  25. Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F (2007) Treatment of travelers’ diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 5:451–456PubMedCrossRefGoogle Scholar
  26. Dupont HL, Petersen A, Zhao J, Mundt A, Jiang ZD, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG, Ballard ED, Totoritis MC (2014) Targeting of rifamycin SV to the colon for treatment of travelers’ diarrhea: a randomized, double-blind, placebo-controlled phase 3 study. J Travel Med 21:369–376PubMedCrossRefGoogle Scholar
  27. El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, Pasetti MF, Chen WH (2013) Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol 20:1764–1770PubMedPubMedCentralCrossRefGoogle Scholar
  28. Ellingsworth LR (2011) Transcutaneous immunization and the travelers’ diarrhea vaccine system: a phase III pivotal efficacy study. In: 6th international conference on vaccines for enteric diseases, VED 2011, Cannes, FranceGoogle Scholar
  29. Evans DG, Evans DJ Jr, Opekun AR, Graham DY (1988) Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiol Immunol 1:117–25PubMedCrossRefGoogle Scholar
  30. Fernandez-Brando RJ, Yamaguchi N, Tahoun A, McAteer SP, Gillespie T, Wang D, Argyle SA, Palermo MS, Gally DL (2016) Type III secretion-dependent sensitivity of Escherichia coli O157 to specific ketolides. Antimicrob Agents Chemother 60:459–470CrossRefGoogle Scholar
  31. Fleckenstein JM, Sheikh A, Qadri F (2014) Novel antigens for enterotoxigenic Escherichia coli vaccines. Expert Rev Vaccines 13:631–639PubMedPubMedCentralCrossRefGoogle Scholar
  32. Flores J, Dupont HL, Jiang ZD, Belkind-Gerson J, Mohamed JA, Carlin LG, Padda RS, Paredes M, Martinez-Sandoval JF, Villa NA, Okhuysen PC (2008) Enterotoxigenic Escherichia coli heat-labile toxin seroconversion in US travelers to Mexico. J Travel Med 15:156–161PubMedCrossRefGoogle Scholar
  33. Flores J, Dupont HL, Jiang ZD, Okhuysen PC, Melendez-Romero JH, Gonzalez-Estrada A, Carrillo I, Paredes M (2011) A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers’ diarrhea in Mexico during the dry season. J Travel Med 18:333–336PubMedCrossRefGoogle Scholar
  34. Flores-Figueroa J, Okhuysen PC, von Sonnenburg F, DuPont HL, Libman MD, Keystone JS, Hale DC, Burchard G, Han PV, Wilder-Smith A, Freedman DO (2011) Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience. Clin Infect Dis 53:523–531PubMedCrossRefGoogle Scholar
  35. Franz E, Veenman C, van Hoek AH, de RodaHusman A, Blaak H (2015) Pathogenic Escherichia coli producing extended-spectrum β-lactamases isolated from surface water and wastewater. Sci Rep 5:14372PubMedPubMedCentralCrossRefGoogle Scholar
  36. Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez-Sandoval FG, Melendez-Romero JH, Jiang ZD, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN, Flyer DC, Andersen BH, Kazempour K, Breisch SA, Glenn GM (2008) Use of a patch containing heat labile toxin from Escherichia coli against travelers’ diarrhoea: a phase II, randomized, double-blind, placebo-controlled field trial. Lancet 371:2019–2025PubMedCrossRefGoogle Scholar
  37. Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, Karch H (2002) Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 185:74–84PubMedCrossRefGoogle Scholar
  38. Fujii J, Naito M, Yutsudo T, Matsumoto S, Heatherly DP, Yamada T, Kobayashi H, Yoshida S, Obrig T (2012) Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin- producing Escherichia coli in mice. Clin Vaccine Immunol 19:1932–1937PubMedPubMedCentralCrossRefGoogle Scholar
  39. Gaastra W, Sommerfelt H, van Dijk L, Kusters JG, Svennerholm AM, Grewal HM (2002) Antigenic variation within the subunit protein of members of the colonization factor antigen I group of fimbrial proteins in human enterotoxigenic Escherichia coli. Int J Med Microbiol 292:43–50PubMedCrossRefGoogle Scholar
  40. Gao X, Cai K, Li T, Wang Q, Hou X, Tian R, Liu H, Tu W, Xiao L, Fang L, Luo S, Liu Y, Wang H (2011) Novel fusion protein protects against adherence and toxicity of enterohemorrhagic Escherichia coli O157:H7 in mice. Vaccine 29:6656–6663PubMedCrossRefGoogle Scholar
  41. Garcia-Angulo VA, Kalita A, Torres AG (2013) Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection. Vaccine 31:3229–3235PubMedPubMedCentralCrossRefGoogle Scholar
  42. Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA (2007) Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun 75:2163–2170PubMedPubMedCentralCrossRefGoogle Scholar
  43. Gohar A, Abdeltawab NF, Fahmy A, Amin MA (2016) Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model. BMC Res Notes 9:1–18CrossRefGoogle Scholar
  44. Güereña-Burgueño F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova GV, Alving CR, Glenn GM (2002) Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 70:1874–1880PubMedPubMedCentralCrossRefGoogle Scholar
  45. Gu J, Liu Y, Yu S, Wang H, Wang Q, Yi Y, Zhu F, Yu XJ, Zou Q, Mao X (2009) Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. Microbes Infect 11:835–841PubMedCrossRefGoogle Scholar
  46. Gu J, Ning Y, Wang H, Xiao D, Tang B, Luo P, Cheng Y, Jiang M, Li N, Zou Q, Mao X (2011) Vaccination of attenuated EIS-producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli in mice. Vaccine 29:7395–7403PubMedCrossRefGoogle Scholar
  47. Gupta P, Singh MK, Singh Y, Gautam V, Kumar S, Kumar O, Dhaked RK (2011) Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice. Vaccine 29:8094–8100PubMedCrossRefGoogle Scholar
  48. Harris JA, Roy K, Woo-Rasberry V, Hamilton DJ, Kansal R, Qadri F, Fleckenstein JM (2011) Directed evaluation of enterotoxigenic Escherichia coli autotransporter proteins as putative vaccine candidates. PLoS Negl Trop Dis 5:1–11CrossRefGoogle Scholar
  49. Harro C, Sack D, Bourgeois AL, Walker R, Denearing B, Feller A, Chakraborty S, Buchwaldt C, Darsley MJ (2011) A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin Vaccine Immunol 18:2118–2127PubMedPubMedCentralCrossRefGoogle Scholar
  50. Harro C, Gutierrez R, Talaat K, Porter C, Riddle M, Maciel M, et al (2015) Protective efficacy of an enterotoxigenic E. coli fimbrial tip adhesin vaccine given with LTR192G by intradermal vaccination against experimental challenge with CFA/I-ETEC in adult volunteers. Presented at the 3rd skin vaccination summitGoogle Scholar
  51. Hauswaldt S, Nitschke M, Sayk F, Solbach W, Knobloch JK (2013) Lessons learned from outbreaks of Shiga toxin producing Escherichia coli. Curr Infect Dis Rep 15:4–9PubMedCrossRefGoogle Scholar
  52. Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker RI, Svennerholm AM (2013) Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 31:2457–2464PubMedCrossRefGoogle Scholar
  53. Hostetter SJ, Helgerson AF, Paton JC, Paton AW, Cornick NA (2014) Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome. BMC Res Notes 7:331. doi: 10.1186/17560500-7-331 PubMedPubMedCentralCrossRefGoogle Scholar
  54. Laird R, Gutierrez R, Savarino SJ, Riddle M, Maciel M (2014) Phenotypic and functional evaluation of T cell responses after intradermal immunization with LTR192G, an attenuated form of the enterotoxigenic E. coli (ETEC) labile toxin (LT), as an adjuvant for an ETEC vaccine. Presented at the American association of immunologist annual meetingGoogle Scholar
  55. Larzábal M, Zotta E, Ibarra C, Rabinovitz BC, Vilte DA, Mercado EC, Cataldi A (2013) Effect of coiled-coil peptides on the function of the type III secretion system-dependent activity of enterohemorragic Escherichia coli O157:H7 and Citrobacter rodentium. Int J Med Microbiol 303:9–15PubMedCrossRefGoogle Scholar
  56. Li X, Wu P, Cheng S, Lv X (2012) Synthesis and assessment of globotriose-chitosan conjugate, a novel inhibitor of Shiga toxins produced by Escherichia coli. J Med Chem 55:2702–2710PubMedCrossRefGoogle Scholar
  57. López EL, Contrini MM, Falaschi A, Inchaurregui E, Galindez R, Ezcurra G, Villena R, Teplitz E, Acuña M, Gonzalez Ayala S, Vergara R, Twele L, Figueroa G, Mellman A, DiLópez EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S (2010) Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 54:239–243PubMedCrossRefGoogle Scholar
  58. López EL, Contrini MM, Falaschi A, Inchaurregui E, Galindez R, Ezcurra G, Villena R, Teplitz E, Acuña M, Gonzalez Ayala S, Vergara R, Twele L, Figueroa G, Mellman A, Distabile L, Reymond D (2015) A phase II study of chimeric monoclonal antibodies to Shiga toxins 1 and 2 administered concomitantly to children with Shiga toxin producing Escherichia coli infection and bloody diarrhea (SHIGATEC trial). In: Abstracts of the 9th international symposium on Shiga toxin (verocytotoxin) producing Escherichia coli infections, Boston, MA, 13–16 September 2015Google Scholar
  59. Lu X, Skurnik D, Pozzi C, Roux D, Cywes-Bentley C, Ritchie JM, Munera D, Gening ML, Tsvetkov YE, Nifantiev NE, Waldor MK, Pier GB (2014) A poly-N-acetylglucosamine–Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli. mBio 5:e00974-14PubMedPubMedCentralCrossRefGoogle Scholar
  60. Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker RI, Holmgren J, Svennerholm AM (2013) Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein. Vaccine 31:1163–1170PubMedCrossRefGoogle Scholar
  61. Luo Q, Kumar P, Vickers TJ, Sheikh A, Lewis WG, Rasko DA, Sistrunk J, Fleckenstein JM (2014) Enterotoxigenic Escherichia coli secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells. Infect Immun 82:509–521PubMedPubMedCentralCrossRefGoogle Scholar
  62. McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM (2007) Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25:3684–3691PubMedCrossRefGoogle Scholar
  63. McNeilly TN, Mitchell MC, Corbishley A, Nath M, Simmonds H, McAteer SP, Mahajan A, Low JC, Smith DG, Huntley JF, Gally DL (2015) Optimizing the protection of cattle against Escherichia coli O157:H7 colonization through immunization with different combinations of H7 flagellin, Tir, intimin-531 or EspA. PLoS One 10(5):e0128391PubMedPubMedCentralCrossRefGoogle Scholar
  64. Mejias MP, Ghersi G, Craig PO, Panek CA, Bentancor LV, Baschkier A, Goldbaum FA, Zylberman V, Palermo MS (2013) Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and Brucella lumazine synthase confers total protection against Shiga toxins in mice. J Immunol 191:2403–2411PubMedCrossRefGoogle Scholar
  65. Mejias MP, Hiriart Y, Lauché C, Fernandez-Brando RJ, Pardo R, Bruballa A, Ramos MV, Goldbaum FA, Palermo MS, Zylberman V (2016) Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS). Sci Rep 6:24913PubMedPubMedCentralCrossRefGoogle Scholar
  66. Melton-Celsa AR, O’Brien AD (2013) New therapeutic developments against Shiga toxin producing Escherichia coli. Microbiol Spectr 2(5)Google Scholar
  67. Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VA, Torricelli G, Cartocci E, Savino S, Scarselli M, Dobrindt U, Hacker J, Tettelin H, Tallon LJ, Sullivan S, Wieler LH, Ewers C, Pickard D, Dougan G, Fontana MR, Rappuoli R, Pizza M, Serino L (2010) Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A 107:9072–9077PubMedPubMedCentralCrossRefGoogle Scholar
  68. Mukhopadhyay S, Linstedt AD (2012) Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 335:332–335PubMedCrossRefGoogle Scholar
  69. Mulvey GL, Marcato P, Kitov PI, Sadowska J, Bundle DR, Armstrong GD (2003) Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 187:640–649PubMedCrossRefGoogle Scholar
  70. Nesta B, Spraggon G, Alteri C, Moriel DG, Rosini R, Veggi D, Smith S, Bertoldi I, Pastorello I, Ferlenghi I, Fontana MR, Frankel G, Mobley HL, Rappuoli R, Pizza M, Serino L, Soriani M (2012) FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 3:e00010–1PubMedPubMedCentralCrossRefGoogle Scholar
  71. Nishikawa K, Matsuoka K, Watanabe M, Igai K, Hino K, Hatano K, Yamada A, Abe N, Terunuma D, Kuzuhara H, Natori Y (2005) Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J Infect Dis 191:2097–2105PubMedCrossRefGoogle Scholar
  72. Norton EB, Lawson LB, Freytag LC, Clements JD (2011) Characterization of a mutant Escherichia coli heat-labile toxin, LT (R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 18:546–551PubMedPubMedCentralCrossRefGoogle Scholar
  73. Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM (2011) Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Scand J Gastroenterol 46:862–868PubMedPubMedCentralCrossRefGoogle Scholar
  74. Ouyang-Latimer J, Jafri S, VanTassel A, Jiang ZD, Gurleen K, Rodriguez S, Nandy RK, Ramamurthy T, Chatterjee S, McKenzie R, Steffen R, DuPont HL (2011) In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother 55:874–878PubMedCrossRefGoogle Scholar
  75. Palermo MS, Exeni R, Fernandez GC (2009) Interventions in hemolytic uremic syndrome (HUS), the major Shiga toxin-related complication in Escherichia coli O157:H7 infections. Expert Rev Anti Infect Ther 7:697–707PubMedCrossRefGoogle Scholar
  76. Paredes-Paredes M, Okhuysen PC, Flores J, Mohamed JA, Padda RS, Gonzalez-Estrada A, Haley CA, Carlin LG, Nair P, DuPont HL (2011a) Seasonality of diarrheagenic Escherichia coli pathotypes in the US students acquiring diarrhea in Mexico. J Travel Med 18:121–125PubMedPubMedCentralCrossRefGoogle Scholar
  77. Paredes-Paredes M, Flores-Figueroa J, Dupont HL (2011b) Advances in the treatment of travelers’ diarrhea. Curr Gastroenterol Rep 13:402–407PubMedCrossRefGoogle Scholar
  78. Paton AW, Chen AY, Wang H, McAllister LJ, Höggerl F, Mayr UB, Shewell LK, Jennings MP, Morona R, Lubitz W, Paton JC (2015) Protection against Shiga-toxigenic Escherichia coli by non-genetically modified organism receptor mimic bacterial ghosts. Infect Immun 83:3526–3533PubMedPubMedCentralCrossRefGoogle Scholar
  79. Qadri F, Wenneras C, Ahmed F, Asaduzzaman M, Saha D, Albert MJ, Sack RB, Svennerholm A (2000) Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Vaccine 18:2704–2712PubMedCrossRefGoogle Scholar
  80. Rasko DA, Moreira CG, de Li R, Reading NC, Ritchie JM, Waldor MK, Williams N, Taussig R, Wei S, Roth M, Hughes DT, Huntley JF, Fina MW, Falck JR, Sperandio V (2008) Targeting QseC signaling and virulence for antibiotic development. Science 321:1078–1080PubMedPubMedCentralCrossRefGoogle Scholar
  81. Ren W, Yu R, Liu G, Li N, Peng Y, Wu M, Yin Y, Li Y, Fatufe AA, Li T (2013) DNA vaccine encoding the major virulence factors of Shiga toxin type 2e(Stx2e)-expressing Escherichia coli induces protection in mice. Vaccine 31:367–372PubMedCrossRefGoogle Scholar
  82. Riddle MS, Savarino SJ (2014) Moving beyond a heat-labile enterotoxin based vaccine against enterotoxigenic Escherichia coli. Lancet Infect Dis 14:174–175PubMedCrossRefGoogle Scholar
  83. Ritchie JM, Greenwich JL, Davis BM, Bronson RT, Gebhart D, Williams SR, Martin D, Scholl D, Waldor MK (2011) An Escherichia coli O157-specific engineered pyocin prevents and ameliorates infection by E. coli O157:H7 in an animal model of diarrheal disease. Antimicrob Agents Chemother 55:5469–5474PubMedPubMedCentralCrossRefGoogle Scholar
  84. Rivas M, Chinen I, Miliwebsky E, Masana M (2014) Risk factors for Shiga toxin-producing Escherichia coli-associated human diseases. Microbiol Spectr 2(5). doi:10.1128/microbiolspec.EHEC-0002-2013Google Scholar
  85. Rojas RL, Gomes PA, Bentancor LV, Sbrogio-Almeida ME, Costa SO, Massis LM, Ferreira RC, Palermo MS, Ferreira LC (2010) Salmonella enteric serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli. Clin Vaccine Immunol 17:529–536PubMedPubMedCentralCrossRefGoogle Scholar
  86. Rossi L, Di Giancamillo A, Reggi S, Domeneghini C, Baldi A, Sala V, Dell’Orto V, Coddens A, Cox E, Fogher C (2013) Expression of verocytotoxic Escherichia coli antigens in tobacco seeds and evaluation of gut immunity after oral administration in mouse model. J Vet Sci 14:263–270PubMedPubMedCentralCrossRefGoogle Scholar
  87. Roy K, Hamilton D, Ostmann MM, Fleckenstein JM (2009a) Vaccination with EtpA glycoprotein or flagellin protects against colonization with enterotoxigenic Escherichia coli in a murine model. Vaccine 27:4601–4608PubMedCrossRefGoogle Scholar
  88. Roy K, Hilliard GM, Hamilton DJ, Luo J, Ostmann MM, Fleckenstein JM (2009b) Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells. Nature 457(7229):594–598PubMedCrossRefGoogle Scholar
  89. Roy K, Kansal R, Bartels SR, Hamilton DJ, Shaaban S, Fleckenstein JM (2011) Adhesin degradation accelerates delivery of heat-labile toxin by enterotoxigenic Escherichia coli. J Biol Chem 286(34):29771–29779PubMedPubMedCentralCrossRefGoogle Scholar
  90. Roy K, Hamilton DJ, Fleckenstein JM (2012) Cooperative role of antibodies against heat-labile toxin and the EtpA adhesin in preventing toxin delivery and intestinal colonization by enterotoxigenic Escherichia coli. Clin Vaccine Immunol 19:1603–1608PubMedPubMedCentralCrossRefGoogle Scholar
  91. Ruan X, Knudsen DE, Wollenberg KM, Sack DA, Zhang W (2014a) Multiepitope fusion antigen induces broadly protective antibodies that prevent adherence of Escherichia coli strains expressing colonization factor antigen I (CFA/I), CFA/II, and CFA/IV. Clin Vaccine Immunol 21:243–249PubMedPubMedCentralCrossRefGoogle Scholar
  92. Ruan X, Robertson DC, Nataro JP, Clements JD, Zhang W, STa Toxoid Vaccine Consortium Group (2014b) Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat labile toxin peptide in inducing neutralizing anti-STa antibodies. Infect Immun 82:1823–1832PubMedPubMedCentralCrossRefGoogle Scholar
  93. Ruan X, Sack DA, Zhang W (2015) Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity. PLoS One 10, e0121623PubMedPubMedCentralCrossRefGoogle Scholar
  94. Rund SA, Rohde H, Sonnenborn U, Oelschlaeger TA (2013) Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104:H4 and O157:H7. Int J Med Microbiol 303:1–8PubMedCrossRefGoogle Scholar
  95. Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Karnell A, Nyquist I, Svennerholm AM (2007) Randomized, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travelers to Guatemala and Mexico. Vaccine 25:4392–4400PubMedCrossRefGoogle Scholar
  96. Sahl JW, Steinsland H, Redman JC (2011) A comparative genomic analysis of diverse clonal types of enterotoxigenic Escherichia coli reveals pathovar-specific conservation. Infect Immun 79:950–960PubMedCrossRefGoogle Scholar
  97. Sato T, Matsui T, Takita E, Kadoyama Y, Makino S, Kato K, Sawada K, Hamabata T (2013) Evaluation of recombinant forms of the Shiga toxin variant Stx2eB subunit and non-toxic mutant Stx2e as vaccine candidates against porcine edema disease. J Vet Med Sci 75:1309–1315PubMedPubMedCentralCrossRefGoogle Scholar
  98. Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF Jr, Abu-Elyazeed R, Rao M, Francis WM, El Mohamady H, Safwat M, Naficy AB, Svennerholm AM, Jertborn M, Lee YJ, Clemens JD (2002) Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J 21:322–330PubMedCrossRefGoogle Scholar
  99. Sheng H, Knecht HJ, Kudva IT, Hovde CJ (2006) Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl Environ Microbiol 72:5359–5366PubMedPubMedCentralCrossRefGoogle Scholar
  100. Sheoran AS, Dmitriev IP, Kashentseva EA, Cohen O, Mukherjee J, Debatis M, Shearer J, Tremblay JM, Beamer G, Curiel DT, Shoemaker CB, Tzipori S (2015) Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication. Infect Immun 83:286–291PubMedCrossRefGoogle Scholar
  101. Silberstein C, Lucero MS, Zotta E, Copeland DP, Lingyun L, Repetto HA, Ibarra C (2011) A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of Shiga toxin 2. Pediatr Res 69:390–394PubMedCrossRefGoogle Scholar
  102. Sillankorva SM, Oliveira H, Azeredo J (2012) Bacteriophages and their role in food safety. Int J Microbiol 2012:863945PubMedPubMedCentralCrossRefGoogle Scholar
  103. Smith MJ, Teel LD, Carvalho HM, Melton-Celsa AR, O’Brien AD (2006) Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24:4122–4129PubMedCrossRefGoogle Scholar
  104. Smith DR, Moxley RA, Peterson RE, Klopfenstein TJ, Erickson GE, Clowser SL (2008) A two-dose regimen of a vaccine against Escherichia coli O157:H7 type III secreted proteins reduced environmental transmission of the agent in a large-scale commercial beef feedlot clinical trial. Foodborne Pathog Dis 5:589–598PubMedCrossRefGoogle Scholar
  105. Snedeker KG, Campbell M, Sargeant JM (2012) A systematic review of vaccinations to reduce the shedding of Escherichia coli O157 in the faeces of domestic ruminants. Zoonoses Public Health 59:126–138PubMedCrossRefGoogle Scholar
  106. Soh HS, Chung HY, Lee HH, Ajjappala H, Jang K, Park JH, Sim JS, Lee GY, Lee HJ, Han YH, Lim JW, Choi I, Chung IS, Hahn BS (2015) Expression and functional validation of heat-labile enterotoxin B (LTB) and cholera toxin B (CTB) subunits in transgenic rice (Oryza sativa). Springerplus 4:148PubMedPubMedCentralCrossRefGoogle Scholar
  107. Stanford K, Bach S, Baah J, McAllister T (2014) A mixture of Lactobacillus casei, Lactobacillus lactis, and Paenibacillus polymyxa reduces Escherichia coli O157:H7 in finishing feedlot cattle. J Food Prot 77:738–744PubMedCrossRefGoogle Scholar
  108. Steel D, Riddle M, Van De Verg L, Bourgeois AL (2012) Vaccine for enteric diseases: a meeting summary. Exp Rev Vaccine 11:407–9CrossRefGoogle Scholar
  109. Steffen R, Cramer JP, Burchard G, Jelinek T, Schwarz U, Ramdas P, Chatterjee C, Jiang ZD, DuPont HL, Dewasthaly S, Westrischnig K, Behrens RH (2013) Efficacy of a travelers’ diarrhea vaccine system in travelers to India. J Travel Med 20:374–379PubMedCrossRefGoogle Scholar
  110. Steffen R, Hill DR, DuPont HL (2015) Traveler’s diarrhea: a clinical review. JAMA 313:71–80PubMedCrossRefGoogle Scholar
  111. Stone SM, Thorpe CM, Ahluwalia A, Rogers AB, Obata F, Vozenilek A, Kolling GL, Kane AV, Magun BE, Jandhyala DM (2012) Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor imatinib. Front Cell Infect Microbiol 2:135PubMedPubMedCentralCrossRefGoogle Scholar
  112. Svennerholm AM, Tobias J (2008) Vaccines against enterotoxigenic Escherichia coli. Exp Rev Vaccine 7:795–804CrossRefGoogle Scholar
  113. Szu SC, Ahmed A (2014) Clinical studies of Escherichia coli O157:H7 conjugate vaccines in adults and young children. Microbiol Spectr 2(6). doi:10.1128/microbiolspec.EHEC-0016-2013Google Scholar
  114. Takeyama N, Kiyono H, Yuki Y (2015) Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccine 3:139–54CrossRefGoogle Scholar
  115. Taylor CM, Bitzan M, Reymond D (2011) SHIGATEC: a phase II study assessing monoclonal antibodies against Shiga toxin 1 and 2 in Shiga toxin-producing E. coli-infected children. Pediatr Nephrol 26:1595–1596Google Scholar
  116. Thomas DE, Elliott EJ (2013) Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review. BMC Public Health 13:799PubMedPubMedCentralCrossRefGoogle Scholar
  117. Thomson DU, Loneragan GH, Thornton AB, Lechtenberg KF, Emery DA, Burkhardt DT, Nagaraja TG (2009) Use of a siderophore receptor and porin proteins-based vaccine to control the burden of Escherichia coli O157:H7 in feedlot cattle. Foodborne Pathog Dis 6:871–877PubMedCrossRefGoogle Scholar
  118. Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DW, Weiss R, Kaskel FJ, Spitzer A, Hirschman GH, Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial (2003) Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290:1337–1344PubMedCrossRefGoogle Scholar
  119. Tremblay JM, Mukherjee J, Leysath CE, Debatis M, Ofori K, Baldwin K, Boucher C, Peters R, Beamer G, Sheoran A, Bedenice D, Tzipori S, Shoemaker CB (2013) A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun 81:4592–4603PubMedPubMedCentralCrossRefGoogle Scholar
  120. Tsuji T, Shimizu T, Sasaki K, Tsukamoto K, Arimitsu H, Ochi S, Shimizu T, Taniguchi K, Noda M, Neri P, Mori H (2008) A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine 26:2092–2099PubMedCrossRefGoogle Scholar
  121. Turner AK, Terry TD, Sack DA, Londono-Arcila P, Darsley MJ (2001) Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. Infect Immun 69:4969–4979PubMedPubMedCentralCrossRefGoogle Scholar
  122. Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H (2004) Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev 17:926–941PubMedPubMedCentralCrossRefGoogle Scholar
  123. Vilte DA, Larzabal M, Garbaccio S, Gammella M, Rabinovitz BC, Elizondo AM, Cantet RJ, Delgado F, Meikle V, Cataldi A, Mercado EC (2011) Reduced faecal shedding of Escherichia coli O157:H7 in cattle following systemic vaccination with gamma-intimin C280 and EspB proteins. Vaccine 29:3962–3968PubMedCrossRefGoogle Scholar
  124. Walker RI (2015) An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children. Vaccine 33:954–965PubMedCrossRefGoogle Scholar
  125. Watanabe-Takahashi M, Sato T, Dohi T, Noguchi N, Kano F, Murata M, Hamabata T, Natori Y, Nishikawa K (2010) An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. Infect Immun 78:177–183PubMedCrossRefGoogle Scholar
  126. WHO (2006) Future directions for research on enterotoxigenic Escherichia coli vaccines in developing countries. WHO Wkly Epidemiol Rec 81:97–104Google Scholar
  127. Wileman BW, Thomson DU, Olson KC, Jaeger JR, Pacheco LA, Bolte J, Burkhardt DT, Emery DA, Straub D (2011) Escherichia coli O157:H7 shedding in vaccinated beef calves born to cows vaccinated prepartum with Escherichia coli O157:H7 SRP vaccine. J Food Prot 74:1599–1604PubMedCrossRefGoogle Scholar
  128. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI (2012) Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 55:33–41PubMedPubMedCentralCrossRefGoogle Scholar
  129. Yu J, Cassels F, Scharton-Kersten T, Hammond SA, Hartman A, Angov E, Corthesy B, Alving C, Glenn GM (2002) Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 70:1056–1068PubMedPubMedCentralCrossRefGoogle Scholar
  130. Zhang W, Sack DA (2015) Current progress in developing subunit vaccines against enterotoxigenic Escherichia coli-associated Diarrhea. Clin Vaccine Immunol 22:983–991PubMedPubMedCentralCrossRefGoogle Scholar
  131. Zhang W, Zhang C, Francis DH, Fang Y, Knudsen D, Nataro JP, Rotertson DC (2010) Genetic fusions of heat-labile (LT) and heat-stable (ST) toxoids of porcine enterotoxigenic Escherichia coli elicit neutralizing anti-LT and anti-STa antibodies. Infect Immun 78:316–325PubMedCrossRefGoogle Scholar
  132. Zhang XH, He KW, Zhao PD, Ye Q, Luan XT, Yu ZY, Wen LB, Ni YX, Li B, Wang XM, Guo RL, Zhou JM, Mao AH (2012) Intranasal immunization with Stx2B-Tir-Stx1B-Zot protein leads to decreased shedding in goats after challenge with Escherichia coli O157:H7. Vet Rec 170:178PubMedCrossRefGoogle Scholar
  133. Zhang C, Knudsen DE, Liu M, Robertson DC, Zhang W, STa Toxoid Vaccine Consortium Group (2013) Toxicity and immunogenicity of enterotoxigenic Escherichia coli heat-labile and heat-stable toxoid fusion 3xSTa (A14Q)-LT (S63K/R192G/L211A) in a murine model. PLoS One 8(10):e77386PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Marina S. Palermo
    • 1
    Email author
  • José Flores-Figueroa
    • 2
  • Mercedes Paredes-Paredes
    • 2
  1. 1.Instituto de Medicina Experimental (IMEX)-CONICET—Academia Nacional de MedicinaBuenos AiresArgentina
  2. 2.JM Research SCCuernavacaMexico

Personalised recommendations